EBA
SUPN icon

Eagle Bay Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Eagle Bay Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-70
Closed -$2K – 1254
2021
Q3 		$2K Buy
+70
New +$1.88K ﹤0.01% 986

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Eagle Bay Advisors's SUPN Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 156 shares — an estimated $5.64K sold.

Eagle Bay Advisors first reported a position in SUPN in Q2 2021 and held it in 15 quarters. The position peaked at $114K in Q4 2022. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • Eagle Bay Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Eagle Bay Advisors sold 156 Supernus Pharmaceuticals shares in Q1 2025, an estimated $5.64K.
  • Eagle Bay Advisors first reported a position in Supernus Pharmaceuticals in Q2 2021 and held it in 15 quarters.
  • Eagle Bay Advisors's Supernus Pharmaceuticals position peaked at $114K in Q4 2022.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.